Costanza Bosi
Azienda Unità Sanitaria Locale Piacenza(IT)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Eosinophilic Disorders and Syndromes, Hemoglobinopathies and Related Disorders
Most-Cited Works
- → Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain(2007)186 cited
- → Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis(2019)145 cited
- → Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS(2009)120 cited
- → Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients(2005)101 cited
- → The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation(2007)90 cited
- → Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis(2017)89 cited
- → Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome–Positive Leukemia(2006)70 cited
- → Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis(2021)69 cited
- → Phosphoinositide-Phospholipase C β1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia(2008)61 cited
- → Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients(2018)54 cited